1046793-56-9

Basic information

• Product Name: 4-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-CYCLOHEXEN-1-YL]-MORPHOLINE
• Synonyms: 4-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-CYCLOHEXEN-1-YL]-MORPHOLINE;4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-enyl)morpholine;4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl)morpholine;4-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-eny
• CAS NO: 1046793-56-9
• Molecular Formula: C₁₆H₂₈BNO₃
• Molecular Weight: 293.20942
• Mol File: 1046793-56-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 348.4±52.0 °C(Predicted)
• Appearance: /
• Density: 1.05±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 7.57±0.20(Predicted)
• CAS DataBase Reference: 4-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-CYCLOHEXEN-1-YL]-MORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-CYCLOHEXEN-1-YL]-MORPHOLINE(1046793-56-9)
• EPA Substance Registry System: 4-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-CYCLOHEXEN-1-YL]-MORPHOLINE(1046793-56-9)

Safety Data

• Hazardous Substances Data: 1046793-56-9(Hazardous Substances Data)

Usage

Uses

4-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)cyclohex-3-en-1-yl]morpholine is a reactant used in the preparation of azaindole derivatives as c-Jun N-terminal kinase inhibitors.

Upstream product

• 127562-53-2 4-(1,4-dioxaspiro<4.5>dec-8-yl)morpholine 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 139025-93-7 4-(morpholin-4-yl)cyclohexan-1-one 
• 1046793-55-8 4-morpholinocyclohex-1-en-1-yl trifluoromethanesulfonate 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1206903-90-3 7-(1-methyl-1H-pyrazol-4-yl)-2-[4-(morpholin-4-yl)cyclohex-1-en-1-yl]-5-(phenylsulfonyl)-5H-pyrrolo[2,3-b]-pyrazine 

Relevant articles and documents

COMPOUNDS

Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

DIAZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE

The invention relates to diazaindole derivatives represented by the general formula (I): where A, E, G, R1, R2, R3 and R4 are defined herein, or pharmaceutically acceptable salts thereof, their use in the inhibition of c-Jun N-terminal kinase (JNK) activity, their use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases, autoimmune diseases and/or organ failure. The invention also provides processes for the manufacture of said diazaindole derivatives and compositions containing them.